PBAC

• Last week, without warning, the federal government significantly restricted the subsidy for an important and safe asthma medicine for children.
• The medicine, fluticasone propionate 50mcg, is a metered-dose inhaler, more commonly known by the brand names Flixotide Junior or Axotide Junior.

The importance of asthma prevention

• When a child has asthma, inflammation and sensitivity causes airway narrowing, which makes it hard to breathe.
• About one in ten Australian children has long-term asthma.
• Children with persistent or severe asthma symptoms need medicines to reduce airway inflammation.

How medicine subsidy decisions work

• To be sold in Australia, all prescription medicines must be registered by the Therapeutic Goods Administration, which assesses the safety and efficacy of the medicine.
• The Pharmaceutical Benefits Scheme (PBS) is a list of medicines our government helps to pay for.
• To get a drug on the list, the manufacturer needs to convince the Pharmaceutical Benefits Advisory Committee (PBAC) the medicine is cost-effective.

The new rules

• The new PBS rules are complicated.
• First, no one over the age of six will get any government subsidy to help with the cost of this medicine.
• Alternatively, the Pharmaceutical Benefits Advisory Committee may place restrictions on the population for whom the medicine is subsidised.

What does it mean for families?

In children over the age of six, several alternative medicines can be prescribed. But in children under five, there are no good alternatives, with no other age-appropriate low-dose steroid inhalers approved by the TGA. In the under-five age group, GPs now have three options if they think their patient needs inhaled steroids:
• The use of private scripts will mean families need to pay whatever their local pharmacy charges them.
• The Australian Asthma Handbook is a project of the National Asthma Council Australia.
• The National Asthma Council Australia has received funding from GSK for some activities, but is not a sponsor of the Handbook.
• The Australian Asthma Handbook is a project of the National Asthma Council Australia.
• The National Asthma Council Australia has received funding from GSK for some activities, but is not a sponsor of the Handbook.

• Additionally, the company added pre-built, third-party PlainID Authorizers ™, which provide access control for vital authorization enforcement patterns, authorization for API Gateways, Microservices, and data lakes.
• "Last year, PlainID made significant headway in high-profile verticals including financial services, government, healthcare and insurance companies," said Oren Ohayon Haren, PlainID's CEO and co-founder.
• Throughout 2022, PlainID announced several strategic moves and partnerships contributing to its customer growth, including:
  The PlainID Technology Network : Developed with PlainID partners, the Network delivers PlainID's cutting-edge technology worldwide to help organizations securely transform authorization and access control.
• iC Consult : Positions PlainID as a strategic reseller and systems integrator for PlainID products, providing the necessary expertise required to consult and deliver on authorization requirements for any customer.

• TEL AVIV, Israel and NEW YORK, Nov. 30, 2022 /PRNewswire/ -- PlainID , The Authorization Company, the leading provider of authorization and policy-based access control, today announced a strategic partnership with Dremio , the easy and open data lakehouse company.
• This partnership enables Dremio clients to leverage PlainID's central access control platform to manage and control access to data via Dremio, allowing for advanced access controls as part of their overall data security strategy.
• PlainID protects that data by externalizing authorization and centralizing its management through its PlainID Authorization Platform and PlainID Authorizers.
• The PlainID Authorization Platform enables rapid business growth by connecting new and legacy technologies with the latest and most advanced authorization features.

• The Authorization Company joins the Identity Defined Security Alliance initiative, highlighting the need for modern identity-based solutions
  TEL AVIV, Israel and NEW YORK, Oct. 11, 2022 /PRNewswire/ -- PlainID , the Authorization Company, has announced that it is now a member of the Identity Defined Security Alliance (IDSA), a vendor-neutral resource for organizations focused on securing digital identities to reduce the risk of an identity-related breach.
• "Even more appropriately, October is Cybersecurity Awareness Month, and IDSA's themeBe Identity Smartemphasizes the importance of why identity should be a critical component of every security strategy.
• The IDSA is a group of identity and security vendors, solution providers, and practitioners that serves as an independent source for thought leadership, expertise, and practical guidance on identity-centric approaches to security.
• Membership in the Identity Defined Security Alliance is open to technology vendors and solution providers committed to the vision of an identity-centric approach to security.